Physician profile
David Gerstein
NPI 1164428660
$9,648.68
in general payments reported to CMS, 2019-2025
22 companies · $726 in 2025
The $726 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $315 · 2021: $690 · 2022: $2,828 · 2023: $3,110 · 2024: $1,608 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,868 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,476 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,867.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,475.75 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $2,065.64 | 2020-2025 | Absorica Ld, Winlevi, Ilumya |
| Abbvie INC. | $1,653.16 | 2019-2025 | |
| Incyte Corporation | $1,340.11 | 2021-2025 | Opzelura |
| Allergan, INC. | $816.10 | 2021-2023 | |
| Janssen Biotech, INC. | $649.07 | 2020-2023 | Tremfya, Remicade, Stelara |
| E.R. Squibb & Sons, L.L.C. | $618.71 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $446.34 | 2019-2025 | |
| Pfizer INC. | $382.56 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $331.05 | 2019-2022 | |
| Amgen INC. | $313.56 | 2022-2024 | Otezla |
| Galderma Laboratories, L.P. | $242.18 | 2024-2025 | Nemluvio, Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $161.47 | 2019-2021 | |
| Leo Pharma INC. | $147.21 | 2022-2023 | Adbry |
| Regeneron Healthcare Solutions, INC. | $123.61 | 2022 | |
| Ucb, INC. | $118.35 | 2024 | Bimzelx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $95.46 | 2023 | Vtama |
| Organogenesis INC. | $35.61 | 2023 | Puraply |
| Novo Nordisk INC | $32.96 | 2020 | |
| Janssen Scientific Affairs, LLC | $24.16 | 2020 | |
| Merz North America, INC. | $21.17 | 2023 | Xeomin |
| Conmed Corporation | $17.91 | 2023 | Visiclear |
| Biofrontera INC. | $12.29 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gerstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.